Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 794-799

  Blanchet, P J ^a   Konitsiotis, S ^a   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; APOMORPHINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG TOLERANCE; DYSKINESIA; FEMALE; MACACA; MALE; MOTOR ACTIVITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; DOPAMINE AGONISTS; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; MPTP POISONING; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0030828601     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. BÉDARD, P. J., DI PAOLO, T., FALARDEAU, P. AND BOUCHER, R.: Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 379: 294-299, 1986.
2. 2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. In Parkinson's Disease: From Basic Research to Treatment, ed. by H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno, Advances in Neurology, Vol. 60, pp. 113-118, Raven Press, New York 1993.
3. 2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. 9: 147-154, 1994.
4. BLANCHET, P. J., BÉDARD, P. J., BRITTON, D. R. AND KEBABIAN, J. W.: Differential effect oif selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-axposed monkeys. J. Pharmacol. Exp. Ther. 267: 275-279, 1993.
5. BLANCHET, P. J., ALLARD, P., GRÉGOIRE, L., TARDIF, F. AND BÉDARD, P. J.: Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can. J. Neurol. Sci. 23: 189-193, 1996.
6. 2 receptor mRNA. Brain Res. 564: 203-219, 1991.
7. BRAVI, D., MOURADIAN, M. M., ROBERTS, J. W., DAVIS, T. L., SOHN, Y. H. AND CHASE, T. N.: Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms. Ann. Neurol. 36: 27-31, 1994.
8. CLARKE, C. E., BOYCE, S., SAMBROOK, M. A., STAHL, S. M. AND CROSSMAN, A. R.: Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmied. Arch. Pharmacol. 338: 35-38, 1988.
9. CLARKE, C. E., BOYCE, S., ROBERTSON, R. G., SAMBROOK, M. A. AND CROSSMAN, A. R.: Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 90: 307-314, 1989.
10. DAVIS, T. L., BRUGHITTA, G., BARONTI, F. AND MOURADIAN, M. M.: Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 41: 630-633, 1991.
11. 3 dopamine receptors in human striatum. Prog. Neuro-Paychopharmacol. Biol. Psychiatry 19: 1147-1154, 1995.
12. GERFEN, C. R. AND KEEFE, K. A.: Neostriatal dopamine receptors. Trends Neurosci. 17: 2-3, 1994.
13. GOMEZ-MANCILLA, B., BOUCHER, R., GAGNON, C., DI PAOLO, T., MARKSTEIN, R. AND BÉDARD, P. J.: Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Mov. Disord. 8: 144-150, 1993.
14. 2 receptors in the monkey brain in HPTP-induced parkinsonism. Brain Res. 602: 290-303, 1993.
15. GRANDAS, F., QUINN, N., CRITCHLEY, P., ROHAN, A., MARSDEN, C. D. AND STAHL, S. M.: Antiparkinsonian activity of a single oral dose of PHNO. Mov. Disord. 2: 47-51, 1987.
16. GRANDAS, F. AND OBESO, J. A.: Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin. Neuropharmacol. 12: 14-22, 1989.
17. GRANDAS, F., GANCHER, S. T., RODRIGUEZ, M., LERA, G., NUTT, J. G. AND OBESO, J. A.: Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin. Neuropharmacol. 15: 13-18, 1992a.
18. GRANDAS, F., GANCHER, S., LERA, G., RODRIGUEZ, M., WOODWARD, W. R., NUTT, J. AND OBESO, J. A.: Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease. Neurology 42: 1287-1290, 1992b.
19. HARDIE, R. J., LEES, A. J. AND STERN, G. M.: On-off fluctuations in Parkinson's disease. Brain 107: 487-506, 1984.
20. 3H]7-hydroxy-N, N-di-n-propyl-2-aminotetralin. Brain Res. 648: 222-228, 1994.
21. HUGHES, A. J., LEES, A. J. AND STERN, G. M.: The motor response to sequential apomorphine in parkinsonian fluctuations. J. Neurol. Neurosurg. Psychiat. 54: 358-360, 1991.
22. HUGHES, A. J., BISHOP, S., KLEEDORFER, B., TURJANSKI, N., FERNANDEZ, W., LEES, A. J. AND STERN, G. M.: Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years. Mov. Disord. 8: 165-170, 1993.
23. HURLEY, M. J., STUBBS, C. M., JENNER, P. AND MARSDEN, C. D.: D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 214: 75-78, 1996.
24. 3 dopamine receptor coupling to adenylyl cyclase. Biochem. Biophys. Res. Commun. 237: 394-399, 1997.
25. LEES, A. J. AND STERN, G. M.: Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 44: 1020-1023, 1981.
26. 1 dopamine receptor gene. Proc. Natl. Acad. Sci. U.S.A. 88: 4205-4209, 1991.
27. LUQUIN, M. R., LAGUNA, J. AND OBESO, J. A.: Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann. Neurol. 31: 551-554, 1992.
28. LUQUIN, M. R., LAGUNA, J., HERRERO, M. T. AND OBESO, J. A.: Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys. J. Neurol. Sci. 114: 40-44, 1993.
29. 2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys. In Parkinson's Disease, ed. by L. Battistin, G, Scarlato, T. Caraceni and S. Ruggieri, Advances in Neurology, Vol. 69, pp. 239-244, Raven Press Ltd., New York, 1996.
30. MIERAU, J.: Pramipexole: A dopamine-receptor agonist for treatment of Parkinson's disease. Clin. Neuropharmacol. 18: (suppl. 1), S195-S206, 1995.
31. MOURADIAN, M. M., JUNCOS, J. L., FABBRINI, G., SCHLEGEL, J., BARTKO, J. J. AND CHASE, T. N.: Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part II. Ann. Neurol. 24: 372-378, 1988.
32. MOURADIAN, M. M., HEUSER, I. J. E., BARONTI, F., GIUFFRA, M., CONANT, K., DAVIS, T. L. AND CHASE, T. N.: Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 54: 401-405, 1991.
33. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U.S.A. 91: 11271-11275, 1994.
34. NEVE, K. A. AND NEVE, R. L.: Molecular biology of dopamine receptors. In The Dopamine Receptors, ed. by K. A. Neve and R. L. Neve, pp. 27-76, Humana Press Inc., Totowa, NJ, 1997.
35. NUTT, J. G. AND HOLFORD, N. H. G.: The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann. Neurol. 39: 561-573, 1996.
36. PARKES, J. D., SCHACHTER, M., MARSDEN, C. D., SMITH, B. AND WILSON, A.: Lisuride in parkinsonism. Ann. Neurol. 9: 48-52, 1981.
37. PEPPE, A., DAMBROSIA, J. M. AND CHASE, T. N.: Risk factors for motor response complications in L-DOPA-treated parkinsonian patients. In Parkinson's Disease: From Basic Research to Treatment, ed. by H. Narabayashi, T. Nagatsu, N. Yanagisawa and Y. Mizuno, Advances in Neurology, Vol. 60, pp. 698-702, Raven Press Ltd., New York, 1993.
38. PUGSLEY, T. A., DAVIS, M. D., AKUNNE, H. C., MACKENZIE, R. G., SHIH, Y. H., DAMSMA, G., WIKSTROM, H., WHETZEL, S. Z., GEORGIC, L. M., COOKE, L. W., DEMATTOS, S. B., CORBIN, A. E., GLASE, S. A., WISE, L. D., DIJKSTRA, D. AND HEFFNER, T. G.: Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128,907. J. Pharmacol. Exp. Ther. 275: 1355-1366, 1995.
39. 2 agonist N-0923 treatment of Parkinson's disease. Neurology 44: (Suppl. 2), A244, 1994.
40. SAUTEL, F., GRIFFON, N., LÉVESQUE, D., PILON, C., SCHWARTZ, J.-C. AND SOKOLOFF, P.: A functional test identifies dopamine agonists selective for D3 versus D2 receptors. NeuroReport 6: 329-332, 1995.
41. SCHWARTZ, J.-C., GIROS, B., MARTRES, M.-P. AND SOKOLOFF, P.: The dopamine receptor family: molecular biology and pharmacology. Semin. Neurosci. 4: 99-108, 1992.
42. 3) as a target for neuroleptics. Nature 347: 146-151, 1990.
43. SURMEIER, D. J., REINER, A., LEVINE, M. S. AND ARIANO, M. A.: Are neostriatal dopamine receptors co-localized? Trends Neurosci. 16: 299-305, 1993.
44. SURMEIER, D. J., SONG, W.-J. AND YAN, Z.: Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. 16: 6579-6591, 1996.
45. 3 receptors. Eur J. Pharmacol. 263: 235-243, 1994.
46. VERHAGEN METMAN, L., LOCATELLI, E. R., BRAVI, D., MOURADIAN, M. M. AND CHASE, T. N.: Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 48: 369-372, 1997a.
47. VERHAGEN METMAN, L., VAN DEN MUNCKHOF, P., KLAASSEN, A. A. G., BLANCHET, P., MOURADIAN, M. M. AND CHASE, T. N.: Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology, 49: 711-713, 1997b.
48. VIDAILHET, M. J., BONNET, A. M., BELAL, S., DUBOIS, B., MARLE, C. AND AGID, Y.: Ropinirole without levodopa in Parkinson's disease. Lancet 1: 316-317, 1990.
49. WATERS, N., SVENSSON, K., HAADSMA-SVENSSON, S. R., SMITH, M. W. AND CARLSSON, A.: The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. [GenSect] 94: 11-19, 1993.
50. WATERS, N., LÖFBERG, L., HAADSMA-SVENSSON, S., SVENSSON, K., SONESSON, C. .AND CARLSSON, A.: Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J. Neural Transm. [GenSect] 98: 39-55, 1994.